To this end, oncogene addicted cancer cell lines including BT-474 (HER2 amplification), EBC-1 (MET amplification) and NCI-H3122 (EML4-ALK fusion) were selected to test the pharmacological efficacy of FS-93. The gene discussed is EML4; the disease is cancer.